DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for melancholia — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMelancholia maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for melancholia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
solute carrier family 6 member 4 (SLC6A4) — SLC6A4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5-cyano-1h-indol-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9HCO · 2.78 Å · ligand 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide (YG7). Experimental structure, not a prediction.
What the evidence adds up to
In a 1998 randomised controlled trial of electroconvulsive therapy for melancholia, three-times-weekly ECT was more efficacious than once-weekly ECT. A high stimulus dose did not improve the efficacy of once-weekly ECT. However, 55% of patients responded to once-weekly ECT, and patients who remitted did so over a comparable time-course regardless of schedule. The authors note a need to identify patients for whom once-weekly ECT may be sufficient.
A 2002 review states that melancholic depression shows a preferential response to physical therapies and a differential response to antidepressant drugs, responding less well to newer narrow-action antidepressant classes. Psychotherapies are considered adjunctive rather than primary. A 2016 personal perspective similarly argues that not all antidepressants are equally potent for melancholia, that response to a single narrow-spectrum antidepressant is low, and that management commonly requires broader-spectrum drugs and augmentation strategies.
A 2025 re-analysis of the STAR*D trial (n=3827) compared remission rates to citalopram, a selective serotonin reuptake inhibitor, in melancholic versus non-melancholic major depressive disorder. The adjusted four-month probability of remission was 26.9% for melancholic patients and 53.8% for non-melancholic patients, a difference of -26.9%. Melancholic patients were more likely to be unemployed, never married, to self-report African American race, and to have higher baseline depressive severity. The authors caution that the melancholia index was derived from symptom items rather than a clinical interview, and that results may not extend to other antidepressants or to psychotic depression.
What is still missing is prospective trial data that stratifies melancholic patients by antidepressant class or dose, and research that identifies which patients can be adequately treated with once-weekly ECT. No trial has yet tested a biomarker or clinical algorithm that reliably predicts which melancholic patient will respond to which specific drug or schedule. Funding for such stratified trials remains limited.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Once vs. three times weekly ECT in melancholia: a randomized controlled trial
AbstractOnce weekly and three times weekly schedules of ECT, each at two stimulus dose levels (high and low), were compared for therapeutic efficacy in melancholia. Three times weekly ECTs were more efficacious than once weekly ECTs. A high stimulus dose did not enhance the efficacy of once weekly ECTs. However, the patients who remitted did so over a comparable time-course regardless of the ECT schedule. Although three times weekly ECTs are superior, 55% of patients responded to once weekly ECTs. There is therefore a need for research to identify the patients for whom once weekly ECT may be sufficient.
Managing melancholic depression: a personal perspective
AbstractOBJECTIVES: The objective of this article is to offer a personal perspective on managing melancholia by interpreting both the limited salient evidence base and offering clinical observations. CONCLUSIONS: It is suggested that medication needs to be prioritised, that not all antidepressants are equally potent for those with melancholia and that as response to a single antidepressant alone (especially a narrow-spectrum one) is low, management commonly requires broader-spectrum antidepressant drugs and augmentation strategies.
Expert Review of Neurotherapeutics · 2002 · 0 citations
Management of melancholia
AbstractThere is increasing recognition that melancholic depression can be distinguished from other depressive types and that it differs from the nonmelancholic disorders in terms of its natural history, spontaneous remission rate, response to placebo and response to psychosocial and physical treatments. As it shows a preferential response to physical therapies, the psychotherapies are best viewed as adjunctive rather than primary treatments for melancholia. Of distinct importance, melancholia appears to show a differential response to differing antidepressant drugs, responding less well to the newer narrow-action antidepressant drug classes. For all these reasons, the management of melancholic depression needs to be distinguished from the management of 'depression' per se.
National Institutes of Health, National Institute of Mental Health (NIMH) Data Archive Repository · 2025 · 0 citations · open access
Melancholic features and treatment outcome to selective serotonin reuptake inhibitors in major depressive disorder: A re-analysis of the STAR*D trial
AbstractBackground Melancholia has been positioned as a qualitatively different form of Major Depressive Disorder (MDD). Some studies have suggested that melancholic MDD patients may show lower remission when receiving treatment with Selective Serotonin Reuptake Inhibitors, but this has not yet been explored in large, representative samples of MDD. Methods We used data from the STAR*D, a multisite randomized controlled trial (n = 4041). We defined melancholia status through the BA Melancholia Empirical Index, constructed using items from the Inventory of Depressive Symptomatology (IDSC). The main outcome of interest was symptomatic remission defined as a Quick Inventory of Depressive Symptoms (Clinician version) (QIDS-C) below or equal to 5. Inverse probability weighting was used to control for confounding. Results 3827 patients were eligible for this study. Melancholic patients were more likely to be unemployed, never married, to self-report an African American race, and to have a higher depressive severity. The adjusted 4-month probability of remission was 26.9 % (22.0, 45.5) for melancholic and 53.8 % (53.2, 58.5), for nonmelancholic patients. Compared with nonmelancholic, the difference in 4-month probability of remission was ?26.9 % (?37.0, ?15.6). Results were consistent across sensitivity analyses. Limitations Items from IDSC were used as a surrogate measure of the BA Melancholia Index, and extrapolation of the results to agents other than citalopram and to psychotic MDD patients requires caution. Conclusions Melancholic MDD patients showed lower probabilities of remission at 4-months receiving treatment with citalopram. The results of this study show how validly subtyping episodes could contribute to the personalized treatment of depression.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
